Boundless Bio, Inc. SEC filings BOLD
Boundless Bio, Inc. has 162 filings in SEC EDGAR's recent list, going back to Mar 12, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 28, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Nov 3, 2026 | — |
| 424B3 | Prospectus | Nov 3, 2026 | — |
| S-4/A | Filing | Nov 2, 2026 | — |
| 425 | Filing | Oct 26, 2026 | — |
| 425 | Filing | Oct 26, 2026 | — |
| S-4 | Registration for a merger or exchange | Oct 8, 2026 | — |
| DRS | Filing | Aug 31, 2026 | — |
| 425 | Filing | Aug 28, 2026 | — |
| 8-K |
Current report
Material agreement
|
Aug 28, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 425 | Filing | Jun 23, 2026 | — |
| 8-K |
Current report
Material agreement, Exit or restructuring costs, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure, Other events
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 8, 2026 | May 8, 2026 |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Agreement ended, New debt
|
Apr 13, 2026 | Apr 13, 2026 |
| 10-K | Annual report | Mar 9, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Mar 9, 2026 | Mar 3, 2026 |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| 10-Q | Quarterly report | Aug 5, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2025 | Aug 5, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2025 | Jun 23, 2025 |
| 8-K |
Current report
Exit or restructuring costs, Other events
|
May 23, 2025 | May 23, 2025 |
| 10-Q | Quarterly report | May 9, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 9, 2025 | May 9, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 23, 2025 |
| EFFECT | Filing | Apr 10, 2025 | — |
| CORRESP | Letter to the SEC | Apr 8, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2025 | — |
| 8-K |
Current report
Material agreement
|
Apr 1, 2025 | Apr 1, 2025 |
| S-3 | Shelf registration | Apr 1, 2025 | — |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2025 | Mar 27, 2025 |
| UPLOAD | Letter from the SEC | Jan 23, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Dec 12, 2024 | Dec 6, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2024 | Oct 11, 2024 |
| 8-K |
Current report
Officer or director change
|
Aug 20, 2024 | Aug 19, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2024 | Aug 12, 2024 |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 13, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 13, 2024 | May 13, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Apr 2, 2024 | Apr 2, 2024 |
| S-8 | Employee stock plan registration | Mar 28, 2024 | — |
| 424B4 | Prospectus | Mar 28, 2024 | — |
| EFFECT | Filing | Mar 27, 2024 | — |
| CERT | Filing | Mar 27, 2024 | — |
| CORRESP | Letter to the SEC | Mar 25, 2024 | — |
| CORRESP | Letter to the SEC | Mar 25, 2024 | — |
| 8-A12B | Filing | Mar 22, 2024 | — |
| S-1/A | Amended registration statement | Mar 21, 2024 | — |
| CORRESP | Letter to the SEC | Mar 15, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2024 | — |
| CORRESP | Letter to the SEC | Mar 8, 2024 | — |
| CORRESP | Letter to the SEC | Mar 6, 2024 | — |
| S-1 | Registration statement | Mar 6, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2024 | — |
| DRS/A | Filing | Jan 23, 2024 | — |
| DRSLTR | Filing | Oct 11, 2023 | — |
| DRS/A | Filing | Oct 11, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2023 | — |
| DRS | Filing | Sep 1, 2023 | — |
| D | Filing | Aug 15, 2023 | — |
| D | Filing | May 4, 2021 | — |
| D | Filing | Mar 12, 2020 | — |
Showing 72 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BOLD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1782303
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.